Cart
sales@molnova.com
Cudarolimab
CAS No. 2244739-29-3
Cudarolimab( —— )
Catalog No. M36834 CAS No. 2244739-29-3
Cudarolimab (IBI-101) is a fully human anti-OX40 antibody with potential immune checkpoint inhibitory and anti-tumor activity for the study of cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 715 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1691 | In Stock |
|
| 50MG | 2213 | In Stock |
|
| 100MG | 3004 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCudarolimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionCudarolimab (IBI-101) is a fully human anti-OX40 antibody with potential immune checkpoint inhibitory and anti-tumor activity for the study of cancer.
-
DescriptionCudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorImmunology/Inflammation related
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2244739-29-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kuang Z, et al. Development and characterization of a novel anti-OX40 antibody for potent immune activation. Cancer Immunol Immunother. 2020 Jun;69(6):939-950. ?
molnova catalog
related products
-
V2 receptor (V2R) a...
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively.
-
Cenobamate
Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.
-
PZ-II-029
PZ-II-029 is a modulator of α6β3γ2-selective GABAA channel.
